These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

820 related items for PubMed ID: 18347005

  • 1. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.
    Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, Missale G, Laccabue D, Zerbini A, Camisa R, Bisagni G, Neri TM, Ardizzoni A.
    J Clin Oncol; 2008 Apr 10; 26(11):1789-96. PubMed ID: 18347005
    [Abstract] [Full Text] [Related]

  • 2. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab.
    Zhang W, Gordon M, Schultheis AM, Yang DY, Nagashima F, Azuma M, Chang HM, Borucka E, Lurje G, Sherrod AE, Iqbal S, Groshen S, Lenz HJ.
    J Clin Oncol; 2007 Aug 20; 25(24):3712-8. PubMed ID: 17704420
    [Abstract] [Full Text] [Related]

  • 3. ABCB1, FCGR2A, and FCGR3A polymorphisms in patients with HER2-positive metastatic breast cancer who were treated with first-line taxane plus trastuzumab chemotherapy.
    Kim JW, Kim JH, Im SA, Kim YJ, Han HS, Kim JS, Han SW, Jeon YK, Oh DY, Han W, Kim TY, Park IA, Noh DY, Bang YJ.
    Oncology; 2012 Aug 20; 83(4):218-27. PubMed ID: 22906996
    [Abstract] [Full Text] [Related]

  • 4. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma.
    Weng WK, Levy R.
    J Clin Oncol; 2003 Nov 01; 21(21):3940-7. PubMed ID: 12975461
    [Abstract] [Full Text] [Related]

  • 5. Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan.
    Bibeau F, Lopez-Crapez E, Di Fiore F, Thezenas S, Ychou M, Blanchard F, Lamy A, Penault-Llorca F, Frébourg T, Michel P, Sabourin JC, Boissière-Michot F.
    J Clin Oncol; 2009 Mar 01; 27(7):1122-9. PubMed ID: 19164213
    [Abstract] [Full Text] [Related]

  • 6. Role of immunoglobulin G fragment C receptor polymorphism-mediated antibody-dependant cellular cytotoxicity in colorectal cancer treated with cetuximab therapy.
    Negri FV, Musolino A, Naldi N, Bortesi B, Missale G, Laccabue D, Zerbini A, Camisa R, Chernyschova N, Bisagni G, Loupakis F, Ruzzo A, Neri TM, Ardizzoni A.
    Pharmacogenomics J; 2014 Feb 01; 14(1):14-9. PubMed ID: 23296156
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Preclinical studies with Fc(gamma)R bispecific antibodies and granulocyte colony-stimulating factor-primed neutrophils as effector cells against HER-2/neu overexpressing breast cancer.
    Stockmeyer B, Valerius T, Repp R, Heijnen IA, Bühring HJ, Deo YM, Kalden JR, Gramatzki M, van de Winkel JG.
    Cancer Res; 1997 Feb 15; 57(4):696-701. PubMed ID: 9044847
    [Abstract] [Full Text] [Related]

  • 9. Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies.
    Esteva FJ, Cheli CD, Fritsche H, Fornier M, Slamon D, Thiel RP, Luftner D, Ghani F.
    Breast Cancer Res; 2005 Feb 15; 7(4):R436-43. PubMed ID: 15987448
    [Abstract] [Full Text] [Related]

  • 10. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer.
    Robert N, Leyland-Jones B, Asmar L, Belt R, Ilegbodu D, Loesch D, Raju R, Valentine E, Sayre R, Cobleigh M, Albain K, McCullough C, Fuchs L, Slamon D.
    J Clin Oncol; 2006 Jun 20; 24(18):2786-92. PubMed ID: 16782917
    [Abstract] [Full Text] [Related]

  • 11. Trastuzumab plus paclitaxel or docetaxel in HER-2-negative/HER-2 ECD-positive anthracycline- and taxane-refractory advanced breast cancer.
    Ardavanis A, Kountourakis P, Kyriakou F, Malliou S, Mantzaris I, Garoufali A, Yiotis I, Scorilas A, Baziotis N, Rigatos G.
    Oncologist; 2008 Apr 20; 13(4):361-9. PubMed ID: 18448549
    [Abstract] [Full Text] [Related]

  • 12. Randomized phase II study comparing efficacy and safety of combination-therapy trastuzumab and docetaxel vs. sequential therapy of trastuzumab followed by docetaxel alone at progression as first-line chemotherapy in patients with HER2+ metastatic breast cancer: HERTAX trial.
    Hamberg P, Bos MM, Braun HJ, Stouthard JM, van Deijk GA, Erdkamp FL, van der Stelt-Frissen IN, Bontenbal M, Creemers GJ, Portielje JE, Pruijt JF, Loosveld OJ, Smit WM, Muller EW, Schmitz PI, Seynaeve C, Klijn JG, Dutch Breast Cancer Trialists' Group (BOOG).
    Clin Breast Cancer; 2011 Apr 20; 11(2):103-13. PubMed ID: 21569996
    [Abstract] [Full Text] [Related]

  • 13. Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2.
    Varchetta S, Gibelli N, Oliviero B, Nardini E, Gennari R, Gatti G, Silva LS, Villani L, Tagliabue E, Ménard S, Costa A, Fagnoni FF.
    Cancer Res; 2007 Dec 15; 67(24):11991-9. PubMed ID: 18089830
    [Abstract] [Full Text] [Related]

  • 14. Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and Phase II Trial.
    Lara PN, Chee KG, Longmate J, Ruel C, Meyers FJ, Gray CR, Edwards RG, Gumerlock PH, Twardowski P, Doroshow JH, Gandara DR.
    Cancer; 2004 May 15; 100(10):2125-31. PubMed ID: 15139054
    [Abstract] [Full Text] [Related]

  • 15. A nonfucosylated anti-HER2 antibody augments antibody-dependent cellular cytotoxicity in breast cancer patients.
    Suzuki E, Niwa R, Saji S, Muta M, Hirose M, Iida S, Shiotsu Y, Satoh M, Shitara K, Kondo M, Toi M.
    Clin Cancer Res; 2007 Mar 15; 13(6):1875-82. PubMed ID: 17363544
    [Abstract] [Full Text] [Related]

  • 16. Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer.
    Wardley AM, Pivot X, Morales-Vasquez F, Zetina LM, de Fátima Dias Gaui M, Reyes DO, Jassem J, Barton C, Button P, Hersberger V, Torres AA.
    J Clin Oncol; 2010 Feb 20; 28(6):976-83. PubMed ID: 20038734
    [Abstract] [Full Text] [Related]

  • 17. Phase II study of capecitabine plus trastuzumab in human epidermal growth factor receptor 2 overexpressing metastatic breast cancer pretreated with anthracyclines or taxanes.
    Schaller G, Fuchs I, Gonsch T, Weber J, Kleine-Tebbe A, Klare P, Hindenburg HJ, Lakner V, Hinke A, Bangemann N.
    J Clin Oncol; 2007 Aug 01; 25(22):3246-50. PubMed ID: 17577021
    [Abstract] [Full Text] [Related]

  • 18. Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer.
    Gasparini G, Gion M, Mariani L, Papaldo P, Crivellari D, Filippelli G, Morabito A, Silingardi V, Torino F, Spada A, Zancan M, De Sio L, Caputo A, Cognetti F, Lambiase A, Amadori D.
    Breast Cancer Res Treat; 2007 Mar 01; 101(3):355-65. PubMed ID: 16850247
    [Abstract] [Full Text] [Related]

  • 19. Clinical efficacy of taxane-trastuzumab combination regimens for HER-2-positive metastatic breast cancer.
    Bullock K, Blackwell K.
    Oncologist; 2008 May 01; 13(5):515-25. PubMed ID: 18515736
    [Abstract] [Full Text] [Related]

  • 20. Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer.
    Burris H, Yardley D, Jones S, Houston G, Broome C, Thompson D, Greco FA, White M, Hainsworth J.
    J Clin Oncol; 2004 May 01; 22(9):1621-9. PubMed ID: 15117984
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 41.